Weight-loss medications may also benefit common medical problem, study finds
A team of international researchers from Ireland and Saudi Arabia followed 262 adult patients with obesity who started taking two GLP-1 medications: liraglutide or semaglutide.
Among the regular drinkers, weekly alcohol intake decreased by 68%, from approximately 23 units of alcohol to around 8 units.
The findings were recently published in the journal Diabetes, Obesity and Metabolism and were also presented last week at the European Congress on Obesity in Spain.
GLP-1 agonists mimic a hormone called GLP-1, which is released from the gastrointestinal system after eating, according to study co-author Carel Le Roux, a professor at University College Dublin.
These medications activate GLP-1 receptors in the brain, decreasing the sense of "reward" people feel after eating or drinking, eventually leading to reduced cravings for both food and alcohol, he told Fox News Digital.
"It is this commonality of function that suggests the GLP-1 receptors in the brain may be a therapeutic target for not just the disease of obesity, but also for alcohol use disorder," the professor said.
Before the participants started the weight-loss drugs, they self-reported their weekly alcohol intake, then were categorized as non-drinkers, rare drinkers or regular drinkers.
Approximately 72% had at least two follow-up visits and 68% reported regular alcohol consumption.
After starting the weight-loss medications, the participants' weekly average alcohol intake decreased by almost two-thirds overall — from approximately 11 units of alcohol to four units after four months of treatment with the GLP-1 agonists.
The reduction in alcohol use was comparable to the decrease that can be achieved by nalmefene, a drug that decreases the "buzz" feeling in people with alcohol use disorder in Europe, according to the researchers.
For the 188 patients who were followed over an average of four months, none had increased their alcohol intake after starting the weight-loss medications.
Patients reported that after an evening meal, they were too full to have their usual drink — and when they did drink, they reported becoming full extremely quickly and drinking at a slower pace, Le Roux noted.
"The findings in this study suggest that we may have just found a therapeutic target for alcohol use disorder."
This suggests that the experience was less enjoyable, partly due to the reduced rate of alcohol absorption.
Some patients also reported that they didn't enjoy the flavor of the alcoholic beverages as much, and also that hangovers were much worse.
All of these experiences showed that the weight-loss medications create "guard rails" that prevent most patients from drinking excessively, giving them a degree of control over their alcohol intake, according to Le Roux.
"The findings in this study suggest that we may have just found a therapeutic target for alcohol use disorder — the GLP-1 receptor," the professor told Fox News Digital.
"This finding potentially opens the possibility of an entirely new pharmacological treatment paradigm, which could be used in conjunction with conventional methods, such as behavior therapy and group support."
The study was limited by its relatively small number of patients, the researchers acknowledged.
Also, the researchers were not able to verify the participants' self-reported alcohol intake, and roughly one-third of them were not available for follow-up.
There was also no control group, which means the researchers couldn't prove that taking weight-loss medication reduces alcohol intake.
"Randomized, controlled trials with diverse patient populations — including patients diagnosed with alcohol use disorder — are needed to provide the quality and quantity of data that could be used to support an application for licensing the medication for the treatment of alcohol use disorder," Le Roux said.
(One such trial is currently underway in Denmark.)
With the current medications available to treat alcohol use disorder, the "major problem" is compliance, Le Roux said — "because the cravings for alcohol tend to come in waves."
"This means a patient might be fully committed to treatment at one point in the week, but then stop taking the medication later in the week when a craving comes," the professor added.
There are currently three FDA-approved medications to treat alcohol use disorder: naltrexone (which helps decrease cravings by reducing the "buzz" feeling that comes with drinking alcohol); disulfiram (which helps some people avoid alcohol by making them feel sick when they drink), and acamprosate (which restores the balance of hormones in the brain to reduce cravings), according to the National Institute on Alcohol Abuse and Alcoholism.
But less than 10% of people with alcohol use disorder get the proper treatment, with many resuming use within the first year of treatment, past research shows.
The main advantage of the GLP-1 agonists is that they only need to be taken once a week and continue to work for the entire week.
Outside experts say the study's findings highlight the potential of weight-loss medications to help treat alcohol use disorder.
"This research suggests a promising ancillary benefit of GLP-1 analogs, potentially influencing cravings for alcohol and offering a new avenue for managing alcohol use disorder," Dr. Fatima Cody Stanford, obesity medicine physician at Massachusetts General Hospital and Harvard Medical School, who was not part of the study, told Fox News Digital.
For more Health articles, visit www.foxnews.com/health
"While the exact mechanisms are still being explored, the findings contribute to our understanding of the broader benefits of GLP-1 analogs beyond obesity treatment," Stanford added.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
42 minutes ago
- Medscape
QoL Deserves More Than a Footnote in Cancer Trials
In a review published in New England Journal of Medicine Evidence , Massimo Di Maio, MD, from the Department of Oncology at the University of Turin in Turin, Italy, and president-elect of the Italian Association of Medical Oncology, offers a detailed analysis of how patient-reported outcomes are used in clinical trials and explains the best practices for interpreting quality-of-life (QoL) data. 'QoL data are increasingly being included in oncology trials,' Di Maio told Univadis Italy, a Medscape Network platform. 'However, the scientific community is less familiar with interpreting — or critically assessing — this type of data compared with more traditional endpoints like progression-free survival or overall survival.' With growing support from scientific societies and regulatory agencies, QoL has become a standard endpoint in many studies. Yet practical guidance on its interpretation remains limited. Di Maio, who also served as lead author of the European Society For Medical Oncology guidelines on the use of patient-reported outcome measures in oncology, views this as a significant gap in the field. 'We must not forget that for many patients — especially those in advanced stages of disease — living well can be just as important, if not more so, than living longer,' he emphasized. He also cautioned that statistical significance does not always translate into meaningful clinical benefit. From Trial Design... To accurately assess QoL and maximize the value of the data, clinical trials must be appropriately designed from the outset. As outlined in the article, phase 3 randomized trials offer the ideal framework for QoL measurement. They allow investigators to compare results between treatment and control groups, tracking changes from baseline and over time. Di Maio explains in the review that randomized trial designs help ensure that any differences observed between study arms are directly linked to the treatment itself. Speaking with Univadis Italy , he also addressed the potential for bias in QoL data collection. 'Some researchers argue that simply knowing they are receiving the experimental treatment may lead patients — perhaps even subconsciously — to perceive a benefit, which could influence patient-reported outcomes like QoL,' he said. Still, Di Maio noted the difficulty in rigorously proving the existence or magnitude of such bias. Ideally, this would be tested by comparing blinded and open-label trials, but these studies are uncommon and logistically challenging. One coordinated analysis, led by Fabio Efficace, PhD, of the Italian Group for Adult Hematologic Diseases, found that trial blinding was not an independent predictor of QoL benefit. While the potential for bias cannot be dismissed, Di Maio believes its real-world impact is likely modest — and that open-label studies can still yield valid and meaningful QoL data. ...To Data Interpretation Few oncology trials designate QoL as a primary endpoint, but this isn't inherently a limitation, Di Maio noted. QoL can still be a valuable secondary endpoint — provided the results are interpreted carefully and in the proper context. One of the central challenges is patient compliance with QoL questionnaires, which tends to be inconsistent. Factors contributing to low completion rates include limited time for clinicians to communicate the importance of QoL data, patient dropout due to disease progression or adverse outcomes, and technical issues such as failures in electronic data capture or patients' unfamiliarity with digital tools. In such cases, Di Maio suggested that having a paper-based backup system can improve data reliability. Ultimately, QoL should not be viewed as an optional or secondary concern, but as a fundamental part of assessing the true value of cancer therapies. Patient-reported outcome measures, while designed to capture quality of life, also offer critical insights into the broader effectiveness and utility of treatments. 'QoL data alone aren't sufficient,' Di Maio emphasized, 'but they are indispensable for understanding the value of a therapy — and for communicating that value clearly to patients.' He concluded that interpreting QoL data accurately is not just a scientific imperative but also an ethical obligation to patients navigating serious and often life-limiting conditions.
Medscape
42 minutes ago
- Medscape
Role of GLP-1 Drugs in Psoriasis and PsA Is Debated
BOGOTÁ, Colombia — Most dermatologists and rheumatologists agree that GLP-1 receptor agonists (GLP-1 RAs), such as liraglutide, semaglutide, and tirzepatide, powerful antidiabetes and weight-loss drugs, have the potential to help some patients with psoriasis and psoriatic arthritis (PsA). Besides mitigating obesity, an established risk factor for psoriasis and PsA, GLP-1 drugs have shown promise in improving psoriasis symptoms and are associated with a lower risk for cardiovascular events, for which people with psoriasis and PsA are at increased risk. Some researchers predict that the drugs will prove to have immunomodulatory effects and become an important addition to current treatments for psoriasis and PsA, even in patients without obesity or diabetes. At the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2025 Annual Meeting and Trainee Symposium, investigators with the GRAPPA dove into hours' worth of discussions and debates about a class of drugs whose emergence Artie Kavanaugh, MD, professor of medicine at the University of California, San Diego, described as a possible 'watershed moment' for the field, akin to the advent of biologic therapies in the 1990s. But with evidence still sparse in patients with psoriatic disease and ancillary concerns about access, cost, patient selection, and physician confidence in prescribing, there was little agreement as to how, whether, or when these drugs should be integrated into clinical practice. A GLP-1 Pioneer Endocrinologist Daniel J. Drucker, MD, professor in the Department of Medicine's Division of Endocrinology, University of Toronto, Ontario, Canada, who discovered some key biological actions of the hormone GLP-1 in the 1980s and '90s, kicked off the conference with a video presentation affirming GLP-1 RAs potential as immunoregulatory agents with anti-inflammatory activity beyond their well-documented effects on body weight. In a 2023 trial of semaglutide in patients with obesity who did not have diabetes, Drucker noted prevention of cardiovascular events and death was seen as independent of weight loss. Similarly, Drucker said, a recent trial in people with metabolic liver disease saw improvements associated with semaglutide that were independent of weight loss. With psoriasis and PsA, randomized controlled trial evidence has yet to support weight-loss independent improvements in symptoms. However, this may soon change: In two separate trials, Eli Lilly is studying a combination of tirzepatide and the interleukin-17A antagonist ixekizumab in patients with overweight or obesity and psoriasis or PsA. The trials will wrap up next summer. Results from trials of GLP-1 inhibitors in nonobese populations, including cohorts of people with Alzheimer's disease, stand to shed further light on their anti-inflammatory effects outside the context of weight loss, Drucker said. 'These medicines are diversifying. We're going to see a wave of new molecules and new indications to treat inflammation,' he predicted, including that of skin, joints, and bone. Still, Drucker cautioned, the drugs 'are not magic bullets, and each condition will need to be assessed on its own.' Real-World Experience From Latin America In a subsequent talk, Enrique Soriano, MD, head of rheumatology at the Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, presented a real-world perspective from Latin America, where GLP-1 drugs are approved in most countries for diabetes or obesity — but still not easy to access and far from becoming a routine part of any rheumatologist's or dermatologist's daily practice. 'We all know that obesity increases the risk of developing psoriatic arthritis in psoriasis patients,' Soriano said — and that weight loss can decrease that risk. 'We also know that treatment response is lower in PsA patients with obesity,' he said. 'But the question for us is whether this drug [class] can improve symptoms and inflammation in our patients and whether this improvement, if it happens, is related to the weight loss or is an independent effect.' Soriano presented a retrospective review from his institution's service of 6800 patients with psoriasis (mostly mild) and 488 with PsA. In each group, just over 1% of patients were taking a GLP-1 RA for obesity, diabetes, or both. While acknowledging the limitations of his study's retrospective design, Soriano noted that 'there was no report of any improvement or change in the skin involvement, and there was also no record of any change in their joint symptoms after starting these drugs.' Soriano also conducted a survey of rheumatologists across several countries in Latin America and found that under a third said that they had encountered a patient whom they thought could benefit from the addition of a GLP-1 drug, while fewer than 10% said that they would feel confident prescribing one. More than half said that if they did think a patient could benefit, they would refer that person to a specialist, such as an endocrinologist. Dermatologist Describes Current Data as 'Weak' Anthony Fernandez, MD, PhD, director of medical and inpatient dermatology at the Cleveland Clinic, Cleveland, praised GLP-1 RAs as 'fascinating medications' with 'a very attractive adverse event profile.' Fernandez cited studies dating back over a decade in which use of these medications has been shown to improve psoriasis. 'And we have some data to suggest that the mechanism…is not entirely related to weight loss. In fact, there's data to support that these medications affect psoriasis-relevant immune pathways. So, in that way, they share similarities with many of the systemic medicines that we already prescribe to treat psoriasis.' Still, Fernandez cautioned, 'The data right now is really weak,' limited to small studies and randomized trials enrolling mostly men. While a few patients in these studies saw dramatic improvements in psoriasis after starting these drugs, 'the reality is that most have, at best, a modest improvement,' he said, 'certainly nowhere near the improvement we are used to seeing' from targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs) and biologic DMARDs (bDMARDs). Moreover, he said, some patients enrolled in the studies were effectively treatment naive. 'That raises a critical question about whether or not a patient [on ts- or bDMARDs] would actually see any further improvement adding GLP-1 RAs,' he said. Fernandez said he thought that dermatologists can safely prescribe and manage GLP-1 therapies. The bigger question is whether they should. 'My opinion is no,' he concluded. 'There will be rare patients who are obese and or have type 2 diabetes and either fail or have a contraindication to all the great systemic medicines we already have available to us. And in those patients, a trial of a GLP-1 RA would seem to be reasonable. But personally, I think we need much, much better data for recommendations concerning general use by dermatologists.' During a question-and-answer period after Soriano's and Fernandez's presentations, other physicians shared their experiences and practical concerns about insurance approvals, referrals, and whether most dermatologists and rheumatologists were simply too busy to manage all the comorbidities of chronic immune-mediated disease for their patients. Some shared anecdotes about patients whose disease had improved after treatment with GLP-1 RAs, including in the absence of other systemic therapies. Patients Intrigued — but Share Clinician's Caution At the same session, Suzanne Grieb, PhD, a patient research participant (PRP) with GRAPPA and assistant professor at Johns Hopkins University, Baltimore , presented results from a survey of her fellow GRAPPA PRPs about their experiences and interests regarding GLP-1 drugs. None of the 11 respondents reported having been prescribed the medications. 'The majority of us described our psoriatic disease as mostly manageable with our current treatment,' Grieb, who has PsA, told the conference. However, that did not mean they weren't curious about GLP-1s. Grieb's survey revealed that while all participants were aware of the importance of exercise and healthy weight in disease management, many continued to struggle with both. Few reported having spoken with their providers about specific interventions. While three respondents expressed interest in taking GLP-1s, they were uncertain whether they would be able to access them. Patients 'are interested in GLP-1s' impact on our psoriatic disease, but also on other elements of our health, thinking more holistically [about] the benefits that could be achieved through these medications,' Grieb said. But the respondents in her survey also reported concerns about adding medications and 'the potential for having to take this medication for the rest of our lives.' In an interview after her presentation, Grieb elaborated on her personal perspective. 'I don't meet the requirement for obesity,' she said. 'But I'm overweight, and I could probably benefit from a GLP-1. Without clear weight-related indications, it's hard, perhaps to be able to justify prescribing it if it's not going to be available. So it's a hard conversation [for clinicians] to bring up with their patients.'
Yahoo
an hour ago
- Yahoo
Parkinson's Disease Has a Smell That Some Dogs Can Detect
Dogs really can be trained to smell Parkinson's disease, according to new research from the United Kingdom. In a double blind trial, a Golden Retriever and a Labrador were able to sniff out which skin swabs came from people with Parkinson's. The smell of the oily secretions seemed to hold secret clues. "The dogs in this study achieved high sensitivity and specificity and showed there is an olfactory signature distinct to patients with the disease," says animal behavioral scientist Nicola Rooney from the University of Bristol. "Sensitivity levels of 70 percent and 80 percent are well above chance, and I believe that dogs could help us to develop a quick, non-invasive, and cost-effective method to identify patients with Parkinson's disease." Related: Today, there is no definitive early test for Parkinson's, which is why scientists are so interested in finding potential biomarkers of the disease on our skin. The knowledge that Parkinson's distinctly changes a person's body odor first came to light roughly a decade ago – all because of one woman. Twelve years before her husband's diagnosis of Parkinson's disease, Joy Milne could sense something was off – specifically, she could smell it. Milne, a Scottish nurse, is known as a 'super-smeller', and in 2016, she became famous among neuroscientists for her extraordinary abilities. In a small pilot study, Milne correctly identified each patient with Parkinson's disease based solely on the scent of their shirts. Her one misidentification turned out to be correct nearly a year later. The news raised an important question: If someone like Milne could smell Parkinson's years before it was diagnosed, could a dog do the same? Dogs are known to have incredible senses of smell, far more powerful than our own. Previous studies have found our pets can smell our stress, our coronavirus infections, and even our cancers – so if a distinct odor for Parkinson's does exist, then maybe a dog can sniff it out, too. In the past decade, a few preliminary trials have provided evidence for that hypothesis. But some only gave limited information on how the dogs were trained and tested. The recent trial from the UK is a collaboration between a program called Medical Detection Dogs and neuroscientists at the University of Manchester. One goal of the research is to figure out what the dogs are actually smelling, and why. In 2019, for instance, researchers at Manchester helped identify which odor compounds set the distinctive smell of Parkinson's apart. Their results were later confirmed by Milne, the serendipitous "super-smeller". A few years on, the odor compounds were used to create a diagnostic 'swab test' for Parkinson's, currently in testing. Perhaps, further down the road, trained dogs could help neuroscientists identify more unique biomarkers of the disease. The trouble is, though, not all canines are up to snuff. In the current trial, only 2 out of 10 dogs made it through training, and neither performed perfectly. One dog, for instance, falsely flagged a tenth of the odor swabs from healthy people as having Parkinson's. The other gave false alarms less than 2 percent of the time. Overall, however, the dogs could smell which person had Parkinson's at a rate well above chance, providing proof of principle. "We are extremely proud to say that once again, dogs can very accurately detect disease," says Claire Guest, the CEO of Medical Detection Dogs. "There is currently no early test for Parkinson's disease and symptoms may start up to 20 years before they become visible and persistent leading to a confirmed diagnosis. "Timely diagnosis is key… " The study was published in the Journal of Parkinson's Disease. Related News Expert Reveals What Can Happen if Testosterone Gel Rubs Onto Others Radioactive Waste Exposed Children in Missouri to Cancer Risks, Study Finds A Single Brain Scan Halfway Through Your Life Can Reveal How Fast You're Aging Solve the daily Crossword
